方達控股(01521.HK)斥最多5.93億港元購美國生物製藥商
方達控股(01521.HK)公布,其全資附屬Frontage Laboratories以現金代價最高7,600萬美元(約5.93億港元),向OpCo及PropertyCo的股東,收購美國目標公司Experimur LLC的100%股東權益。
Experimur LLC專門從事藥物發現及開發活動的生物製藥公司提供毒理學檢測、研究及實驗室服務。
公司認為,收購事項將擴大集團在藥物安全性評估、毒理學服務以及其他藥物發現及開發輔助服務的能力,並將增強集團通過其他科學家、設備及設施提供該等服務的能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.